BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1909 related articles for article (PubMed ID: 25434967)

  • 1. Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
    Haidar A; Legault L; Messier V; Mitre TM; Leroux C; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Jan; 3(1):17-26. PubMed ID: 25434967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial.
    Haidar A; Legault L; Matteau-Pelletier L; Messier V; Dallaire M; Ladouceur M; Rabasa-Lhoret R
    Lancet Diabetes Endocrinol; 2015 Aug; 3(8):595-604. PubMed ID: 26066705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial.
    Russell SJ; Hillard MA; Balliro C; Magyar KL; Selagamsetty R; Sinha M; Grennan K; Mondesir D; Ekhlaspour L; Zheng H; Damiano ER; El-Khatib FH
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):233-243. PubMed ID: 26850709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and Dual-Hormone Artificial Pancreas for Overnight Glucose Control in Type 1 Diabetes.
    Haidar A; Rabasa-Lhoret R; Legault L; Lovblom LE; Rakheja R; Messier V; D'Aoust É; Falappa CM; Justice T; Orszag A; Tschirhart H; Dallaire M; Ladouceur M; Perkins BA
    J Clin Endocrinol Metab; 2016 Jan; 101(1):214-23. PubMed ID: 26523526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial.
    El-Khatib FH; Balliro C; Hillard MA; Magyar KL; Ekhlaspour L; Sinha M; Mondesir D; Esmaeili A; Hartigan C; Thompson MJ; Malkani S; Lock JP; Harlan DM; Clinton P; Frank E; Wilson DM; DeSalvo D; Norlander L; Ly T; Buckingham BA; Diner J; Dezube M; Young LA; Goley A; Kirkman MS; Buse JB; Zheng H; Selagamsetty RR; Damiano ER; Russell SJ
    Lancet; 2017 Jan; 389(10067):369-380. PubMed ID: 28007348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial.
    Haidar A; Legault L; Dallaire M; Alkhateeb A; Coriati A; Messier V; Cheng P; Millette M; Boulet B; Rabasa-Lhoret R
    CMAJ; 2013 Mar; 185(4):297-305. PubMed ID: 23359039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient 60-hour day-and-night glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or sensor-augmented pump therapy in adults with type 1 diabetes: An open-label, randomised, crossover, controlled trial.
    Haidar A; Messier V; Legault L; Ladouceur M; Rabasa-Lhoret R
    Diabetes Obes Metab; 2017 May; 19(5):713-720. PubMed ID: 28094472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial.
    Kropff J; Del Favero S; Place J; Toffanin C; Visentin R; Monaro M; Messori M; Di Palma F; Lanzola G; Farret A; Boscari F; Galasso S; Magni P; Avogaro A; Keith-Hynes P; Kovatchev BP; Bruttomesso D; Cobelli C; DeVries JH; Renard E; Magni L;
    Lancet Diabetes Endocrinol; 2015 Dec; 3(12):939-47. PubMed ID: 26432775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overnight Glucose Control with Dual- and Single-Hormone Artificial Pancreas in Type 1 Diabetes with Hypoglycemia Unawareness: A Randomized Controlled Trial.
    Abitbol A; Rabasa-Lhoret R; Messier V; Legault L; Smaoui M; Cohen N; Haidar A
    Diabetes Technol Ther; 2018 Mar; 20(3):189-196. PubMed ID: 29393675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of a dual-hormone artificial pancreas with dosing adjustment during exercise compared with no adjustment and sensor-augmented pump therapy.
    Jacobs PG; El Youssef J; Reddy R; Resalat N; Branigan D; Condon J; Preiser N; Ramsey K; Jones M; Edwards C; Kuehl K; Leitschuh J; Rajhbeharrysingh U; Castle JR
    Diabetes Obes Metab; 2016 Nov; 18(11):1110-1119. PubMed ID: 27333970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of single-hormone and dual-hormone artificial pancreas during continuous and interval exercise in adult patients with type 1 diabetes: randomised controlled crossover trial.
    Taleb N; Emami A; Suppere C; Messier V; Legault L; Ladouceur M; Chiasson JL; Haidar A; Rabasa-Lhoret R
    Diabetologia; 2016 Dec; 59(12):2561-2571. PubMed ID: 27704167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible insulin therapy with a hybrid regimen of insulin degludec and continuous subcutaneous insulin infusion with pump suspension before exercise in physically active adults with type 1 diabetes (FIT Untethered): a single-centre, open-label, proof-of-concept, randomised crossover trial.
    Aronson R; Li A; Brown RE; McGaugh S; Riddell MC
    Lancet Diabetes Endocrinol; 2020 Jun; 8(6):511-523. PubMed ID: 32445738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A fully artificial pancreas versus a hybrid artificial pancreas for type 1 diabetes: a single-centre, open-label, randomised controlled, crossover, non-inferiority trial.
    Tsoukas MA; Majdpour D; Yale JF; Fathi AE; Garfield N; Rutkowski J; Rene J; Legault L; Haidar A
    Lancet Digit Health; 2021 Nov; 3(11):e723-e732. PubMed ID: 34580055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study.
    Thabit H; Lubina-Solomon A; Stadler M; Leelarathna L; Walkinshaw E; Pernet A; Allen JM; Iqbal A; Choudhary P; Kumareswaran K; Nodale M; Nisbet C; Wilinska ME; Barnard KD; Dunger DB; Heller SR; Amiel SA; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):701-9. PubMed ID: 24943065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials.
    Weisman A; Bai JW; Cardinez M; Kramer CK; Perkins BA
    Lancet Diabetes Endocrinol; 2017 Jul; 5(7):501-512. PubMed ID: 28533136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of suspend-before-low insulin pump technology in hypoglycaemia-prone adults with type 1 diabetes (SMILE): an open-label randomised controlled trial.
    Bosi E; Choudhary P; de Valk HW; Lablanche S; Castañeda J; de Portu S; Da Silva J; Ré R; Vorrink-de Groot L; Shin J; Kaufman FR; Cohen O;
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):462-472. PubMed ID: 31047902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial.
    Tauschmann M; Thabit H; Bally L; Allen JM; Hartnell S; Wilinska ME; Ruan Y; Sibayan J; Kollman C; Cheng P; Beck RW; Acerini CL; Evans ML; Dunger DB; Elleri D; Campbell F; Bergenstal RM; Criego A; Shah VN; Leelarathna L; Hovorka R;
    Lancet; 2018 Oct; 392(10155):1321-1329. PubMed ID: 30292578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day-and-night glycaemic control with closed-loop insulin delivery versus conventional insulin pump therapy in free-living adults with well controlled type 1 diabetes: an open-label, randomised, crossover study.
    Bally L; Thabit H; Kojzar H; Mader JK; Qerimi-Hyseni J; Hartnell S; Tauschmann M; Allen JM; Wilinska ME; Pieber TR; Evans ML; Hovorka R
    Lancet Diabetes Endocrinol; 2017 Apr; 5(4):261-270. PubMed ID: 28094136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial.
    Haidar A; Tsoukas MA; Bernier-Twardy S; Yale JF; Rutkowski J; Bossy A; Pytka E; El Fathi A; Strauss N; Legault L
    Diabetes Care; 2020 Mar; 43(3):597-606. PubMed ID: 31974099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies.
    Hovorka R; Kumareswaran K; Harris J; Allen JM; Elleri D; Xing D; Kollman C; Nodale M; Murphy HR; Dunger DB; Amiel SA; Heller SR; Wilinska ME; Evans ML
    BMJ; 2011 Apr; 342():d1855. PubMed ID: 21493665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 96.